Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

761

Therapeutic Potential of Astaxanthin in Diabetic Kidney Disease

Yuji Naito1, Kazuhiko Uchiyama2, Osamu Handa3

  • 1Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. ynaito@koto.kpu-m.ac.jp.

Advances in Experimental Medicine and Biology
|March 30, 2021
PubMed

Insights

Astaxanthin, a potent carotenoid, protects against diabetic kidney disease (DKD) by reducing mitochondrial oxidative stress in diabetic mice. It normalizes gene expression and inhibits harmful protein modifications, preserving kidney health.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Background:

  • Diabetic kidney disease (DKD) is a major complication of diabetes.
  • Mitochondrial dysfunction and oxidative stress play key roles in DKD pathogenesis.
  • Astaxanthin is a natural carotenoid with known antioxidant properties.

Purpose of the Study:

  • To investigate the protective effects of astaxanthin on DKD in a diabetic mouse model.
  • To elucidate the molecular mechanisms underlying astaxanthin's renoprotective action.

Main Methods:

  • DNA microarray analysis to assess gene expression changes in renal glomerular cells.
  • Proteomic analysis to identify and quantify modified proteins.
  • Induction of DKD in diabetic mice models.

Main Results:

  • Astaxanthin treatment significantly decreased the expression of upregulated genes in the mitochondrial oxidative phosphorylation pathway.
  • Astaxanthin inhibited the increase of 4-hydroxy-2-nonenal (HNE)- and Nε-(hexanonyl)lysine (HEL)-modified proteins.
  • These molecular changes correlated with a protective effect against hyperglycemia-induced DKD.

Conclusions:

  • Astaxanthin demonstrates potent renoprotective effects against DKD.
  • The mechanism involves the attenuation of mitochondrial oxidative stress and related cellular dysfunction.
  • Astaxanthin holds promise as a therapeutic agent for managing diabetic kidney complications.
Keywords:
4-Hydroxy-2-nonenalDiabetic kidney diseaseGlomerular cellMitochondrial oxidative phosphorylation

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

419
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

398

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
179
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
127
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
653
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
1.8K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
589